Timothy Fenske, MD

Sarah Cannon Transplant and Cell Therapy Program at Methodist Hospital

Hematologist-oncologist

Published Articles (1)

Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter

June 25, 2026

Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.